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OBJECTIVES	 The study was conducted to determine if the capillary density of skeletal muscle is a potential 
contributor to exercise intolerance in class II–III chronic heart failure (CHF). 
BACKGROUND	 Previous studies suggest that abnormalities in skeletal muscle histology, contractile protein 
content and enzymology contribute to exercise intolerance in CHF. 
METHODS	 The present study examined skeletal muscle biopsies from 22 male patients with CHF 
compared with 10 age-matched normal male control patients. Aerobic capacities, myosin 
heavy chain (MHC) isoforms, enzymes, and capillary density were measured. 
RESULTS	 The patients with CHF demonstrated a reduced peak oxygen consumption when compared 
to controls (15.0 � 2.5 vs. 19.8 � 5.0 ml�kg�1�min�1, p  �0.05). Using cell-speciﬁc 
antibodies to directly assess vascular density, there was a reduction in capillary density in CHF 
measured as the number of endothelial cells/ﬁber (1.42 � 0.28 vs. 1.74 � 0.35, p � 0.02). 
In CHF, capillary density was inversely related to maximal oxygen consumption (r � 0.479, 
p � 0.02). The MHC IIx isoform was found to be higher in patients with CHF versus normal 
subjects (28.5 � 13.6 vs. 19.5 � 9.4, p �0.05). 
CONCLUSIONS	 There was a signiﬁcant reduction in microvascular density in patients with CHF compared 
with the control group, without major differences in other usual histologic and biochemical 
aerobic markers. The inverse relationship with peak oxygen consumption seen in the CHF 
group suggests that a reduction in microvascular density of skeletal muscle may precede other 
skeletal muscle alterations and play a critical role in the exercise intolerance characteristic of 
patients with CHF. (J Am Coll Cardiol 1999;33:1956 –63) © 1999 by the American College 
of Cardiology 
A Contributing Mechanism for Exercise Intolerance in Class II–III 
Chronic Heart Failure Independent of Other Peripheral Alterations 
Exertional fatigue or exercise intolerance is a common heart failure (1–4). Left ventricular ejection fraction does 
presenting symptom in over one-third of patients with not correlate with exercise tolerance, and increases in 
chronic heart failure (CHF). Although medical therapy has pulmonary capillary wedge pressure during exercise are not 
reduced mortality, exercise intolerance remains a major responsible for exercise limitation in patients limited by 
source of morbidity in this population. It is well accepted dyspnea. Therefore, although previously studied by many 
that the severity of left ventricular systolic dysfunction, as groups, the complete mechanisms for exercise intolerance in 
measured by left ventricular ejection fraction (LVEF) or patients with CHF remain unknown. 
pulmonary capillary wedge pressure, cannot alone explain Previous studies comparing class II–IV CHF patients to 
the compromised functional capacity observed in chronic active normals have demonstrated differences in exercise 
tolerance accompanied by alterations in skeletal muscle 
histology and biochemistry (5–9). These alterations include 
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Abbreviations and Acronyms 
A-VO2 � arteriovenous-oxygen difference 
CHF � chronic heart failure 
LVEF � left ventricular ejection fraction 
MET � metabolic equivalent 
MHC � myosin heavy chain 
NMR � nuclear magnetic resonance 
we concluded that overall oxygen diffusion distances were 
unchanged in patients with CHF. Mancini et al. (8) 
observed no difference in the number of capillaries per 
muscle ﬁber, but did observe an increase in capillaries/mm2 
cross-sectional area in CHF. Lipkin et al. (9) observed 
capillaries per muscle ﬁber to be normal in CHF, whereas 
Drexler et al. (7) found capillary length density (number of 
capillaries per unit volume of muscle tissue) to be reduced in 
CHF. Vascular density in these studies was assessed by 
methods that detect components of the basement mem­
brane (i.e., periodic acid–Schiff staining), not by a direct 
examination for endothelial cells. Therefore, capillary den­
sity warrants further investigation to explain the exercise 
intolerance seen in patients with CHF. 
The vascular bed in skeletal muscle functions mainly to 
supply oxygen to muscle ﬁbers. Capillary density strongly 
correlates with human skeletal muscle oxidative capacity 
(10,11). Therefore, it is also possible that it may be 
important in determining exercise tolerance in CHF inde­
pendent of other biochemical or histological changes in the 
skeletal muscle. The purpose of this investigation was to 
determine if the capillary density of skeletal muscle is a 
potential contributor to exercise intolerance in patients with 
ambulatory class II–III CHF. We hypothesized that capil­
lary density in skeletal muscle of patients with CHF would 
be reduced and positively correlated with measures of 
exercise tolerance. 
METHODS 
Patient population. Twenty-two male patients (12 from 
Duke Medical Center in Durham, North Carolina and 10 
from Henry Ford Hospital in Detroit, Michigan) with class 
II–III CHF due to left ventricular systolic dysfunction 
(LVEF � 35%) and 10 (from Duke Medical Center) 
age-matched male sedentary normals participated in the 
study. All subjects with CHF were on a stable medical 
regimen for a minimal of three months before the study. 
Twenty were on digoxin, 21 were taking diuretics, 21 
angiotensin-converting enzyme inhibitors, and 12 were 
taking long-acting nitrates. All subjects with CHF were 
symptom limited by dyspnea or leg fatigue. Thirteen pa­
tients had ischemic cardiomyopathy and nine had idiopathic 
cardiomyopathy. All subjects were free of claudication, rales 
and peripheral bruits. Exclusion criteria included insulin-
dependent diabetes mellitus, clinically signiﬁcant chronic 
obstructive pulmonary disease and peripheral vascular dis­
ease. All patients with CHF were sedentary and not 
involved in any form of regular physical activity. There was 
no indication of cardiopulmonary dysfunction in normal 
subjects by either history or physical examination, and none 
exhibited symptoms of ischemic heart disease. Normal 
subjects were on no medications and none were engaged in 
any type of regular aerobic exercise. 
Study protocol. All studies were performed under research 
protocols approved by the Institutional Review boards of the 
Duke University, the Durham Veterans Administration 
Medical Center and Henry Ford Hospital. Each subject was 
informed of testing protocols and the potential risks and 
beneﬁts of participation. All subjects provided written 
consent before participation. 
Exercise testing. All patients with CHF underwent graded 
upright bicycle exercise to a symptom-limited maximum on 
a cycle ergometer (Fitron, Lumex, Ronkonkoma, New 
York, or Monarck, Varberg, Sweden) with a 12-lead elec­
trocardiogram as previously described in our laboratory (5). 
The workload began at 150 kpm/min and advanced in 
3-min stages of 150 kpm/min. Equilibrium radionucleotide 
angiograms were obtained for Duke University subjects at 
rest using a low-energy mobile gamma camera. Expired 
gases were analyzed continuously using a Sensormedics 
4400 unit (Yorba Linda, California). Henry Ford patients 
were included if LVEF was �35% via equilibrium radio-
nucleotide angiograms or catheterization within six months, 
or an echocardiogram showing LVEF �30%. 
Muscle biopsies. Biopsy samples were obtained from the 
vastus lateralis using a modiﬁed Bergstrom needle technique 
(12). Biopsy sites were anesthetized with a 2% lidocaine 
solution, and 0.5-cm incisions were made through the skin 
and fascia lata. The needle was consistently inserted to a 
depth of 40 to 60 mm. Samples were then mounted in cross 
section, in optimal cutting temperature (OCT) compound 
(Miles Pharmaceutical, West Haven, Connecticut) beds, 
and snap-frozen at �80°C. 
Immunohistochemical analysis of vascular density. Vas­
cular density, expressed as endothelial cells/muscle ﬁber, was 
determined by examining the total number of endothelial 
cells relative to the total number of muscle ﬁbers via light 
microscopy. Endothelial cells were identiﬁed in histologic 
sections using immunohistological techniques with an 
endothelial-cell-speciﬁc monoclonal antibody in methods 
previously described (13). Sections were cut throughout the 
tissue block for analysis, ensuring a homogenous sample of 
the block. Brieﬂy, slides were allowed to come to room 
temperature, placed in ice-cold acetone for 2 min and 
phosphate buffered saline (PBS) for 5 min. Blocking solu­
tion (10% horse serum in PBS) was applied for 1 h at  room 
temperature. The primary antibody CD-31 (DACO) was 
applied for 30 min at room temperature, followed by 
sequential incubation with a biotinylated anti-mouse IgG 
and ABC reagent, according to the manufacturer’s speciﬁ­
cations (Vectastain ABC kit, Vector Laboratories, Burlin­
game, California). Levamisole was added to block endoge­
nous alkaline phosphatase activity and immune complexes 
were localized using the chromogenic alkaline phosphatase 
substrate Vector Red (Vector Laboratories). When counter­
stained with hematoxolin, dehydrated and mounted with 
Permount (Fisher Scientiﬁc) the antigen appears to be red 
and the nuclei appears to be blue. A murine IgG monoclo­
nal antibody served as a negative control (13). A minimum 
of six 200� ﬁelds were counted. The mean number of ﬁbers 
counted for each sample was 40. Only ﬁelds that were in 
cross section were counted. Fields not oriented in cross 
section were excluded from analysis. A random number of 
samples were chosen for a blinded repeat analysis. Intraob­
server variability on samples chosen for blind repeat analysis 
was 5%. To exclude differences in cross-sectional area of 
muscle ﬁbers between CHF and normals, randomly selected 
slides in cross section were projected and digitized. The 
stained slide of human muscle was placed on the Olympus 
1X70 microscope (Sterling, Virginia) and transferred onto a 
computer screen at a magniﬁcation of 100� through an 
Optronics Engineering DEI-750 camera (Goleta, Califor­
nia) to the Adobe Premiere 4.2.1 program (San Jose, 
California). Within this program the image of the muscle 
ﬁber was captured and saved to the Adobe Photoshop LE 
program, then opened into the NIH Image 1.6/ppc pro­
gram. In the NIH Image program the individual muscle 
ﬁber was outlined and the total area was calculated. 
Myosin heavy-chain analysis. Muscle biopsy samples 
(�30 mg each) were minced with razor blades on a chilled 
glass plate and transferred to microcentrifuge tubes. The 
samples were washed and resuspended twice in a rigor 
solution containing protease inhibitors (100 mmol/liter 
NaCl; 15 mmol/liter Tris pH 8.0; 2 mmol/liter MgCl2; 4  
mmol/liter EGTA; 7 mmol/liter B-mercaptoethanol, 
PMSF, leupeptin, antipain and pepstatin). Following the 
initial washes, the pellets were resuspended in rigor solution 
containing 2% Triton X-100 (a detergent) to solubilize 
membrane-bound components, and then washed two more 
times in rigor buffer. Aliquots of myoﬁbrils were dissolved 
in a sodium dodecyl sulfate–polyacrylamide (SDS) gel-
loading buffer and frozen at �80°C. 
Myosin heavy-chain (MHC) isoforms were resolved on 
7.4% polyacrylamide gels containing 35% glycerol as de­
scribed by Talmadge et al. (14). Following electrophoresis, 
gels were ﬁxed in 15% acetic acid and stained with Coo­
massie Brilliant Blue G-250 (Bio-Rad, Hercules, Califor­
nia). The MHC isoforms I, IIa, and IIx were identiﬁed by 
order of migration according to Ennion et al. (15) and 
Smerdu et al. (16). Gels were scanned electronically, and 
relative proportions of MHC isoform were measured using 
NIH Image 1.60 for Macintosh and Jandel PeakFit for 
Windows. 
Enzymology. For the measurement of the maximal activ­
ities of several enzymes representative of different energy 
pathways, frozen tissue samples were homogenized in a 
phosphate buffer (pH 7.4) containing 0.02% bovine serum 
albumin (BSA), 5 mmol/liter B-mercaptoethanol, and 
0.05 mmol/liter EDTA and diluted (1:100) in 20 mmol/ 
liter imidazole buffer with 0.02% BSA (17). 
Phosphofructokinase and succinic dehydrogenase activi­
ties were performed on the fresh homogenates while the 
enzymes malate dehydrogenase, 3-hydoxyl-CoA dehydro­
genase, phosphorylase, hexokinase, and lactate dehydroge­
nase were performed on the frozen homogenates stored 
(�80°C) until the time of analysis. Enzyme assays were 
performed ﬂuorometrically using an end point assay at a 
temperature of 23°C as outlined previously (17,18). 
The maximal activity of one enzyme, cytochrome C 
oxidase, was measured spectrophotometrically at 38°C 
using a reaction medium that consisted of 970 �l of  
10 mmol/liter potassium phosphate buffer (pH 7.0) and 
20 �l of 1 mmol/liter solution of reduced cytochrome C 
(Sigma C-2506 (St. Louis, Missouri)). The assay was 
initiated by adding 10 �l of the sample (diluted 10:1 in 
phosphate buffer) to the reaction medium (1 mmol/liter) 
and the decrease in absorbance was measured at a 
wavelength of 550 nm for 3 min. Maximum activity was 
calculated using the measured slope and the extinction 
coefﬁcient of reduced cytochrome C at 550 nm. 
Statistical analysis. Intergroup comparisons were per­
formed using the unpaired Student t test. Intragroup CHF 
comparisons were made using the nonparametric Mann-
Whitney U test. A p value �0.05 was considered signiﬁcant. 
To determine the relation of variables, Pearson correlations 
were performed on linear regressions between the measured 
biochemical and histologic markers and aerobic capacity. 
For purposes of the analysis of relationships between aerobic 
capacity and vascular density we divided the CHF patients 
into three groups: those with a range in exercise capacity of 
one metabolic equivalent (MET) surrounding the mean for 
the entire group (4.25 METs) and those outside this range. 
Thus, the groups analyzed were those with exercise capac­
ities �4 METs, 4 to 5 METs, and �5 METs. 
RESULTS 
Table 1 contains demographic data for the CHF patients 
and normal controls. There were no signiﬁcant differences 
in age, weight, height or body surface area (BSA) 
between the two groups. Subjects with CHF had a peak 
VO2 of 15.0 � 2.5 ml/kg/min versus 19.8 � 5.0 for 
normals (p � 0.05) and a LVEF of 22.5 � 8.4% vs. 
56.0 � 7.9 (p � 0.001). 
Table 2 provides a summary of the relative content of 
MHC type I, type IIa, and type IIx in the skeletal muscles 
of individuals with CHF and normal subjects. Relative 
percentages for MHC I and MHC IIa were all similar 
between groups. The relative percentage of MHC IIx 
Table 1. Subject Demographic Data (Mean � SD) 
Subject Age (yrs) BSA (m2) Weight (kg) Height (cm) 
VO2max 
(ml�kg�1�min�1) LVEF (%) 
CHF 60.5 � 10.9 2.0 � 0.2 87.5 � 16.5 175.6 � 7.5 15.0 � 2.5 22.5 � 8.4 
Normals 61.1 � 6.6 2.0 � 0.2 84.1 � 12.5 176.7 � 10.2 19.8 � 5.0* 56.0 � 7.9† 
*Denotes p �0.05. †Denotes p �0.001. 
isoform was signiﬁcantly higher in the CHF group 
(patients with CHF 28.3 � 13.6% vs. normals 21.5 � 
6.5%, p � 0.05). 
Table 3 contains aerobic and glycolytic enzyme activities 
in the two groups. One of four glycolytic enzymes mea­
sured, phosphorylase, was found to be elevated in CHF 
(p �0.05). Two out of ﬁve aerobic enzymes, 3-hydroxyl-
CoA dehydrogenase (p � 0.001) and succinic dehydro­
genase (p � 0.05), were lower in patients with CHF. 
Vascular density measurements for each of the individual 
patients with CHF and normal subjects are shown in Figure 
1. Overall, the number of endothelial cells/muscle ﬁber was 
1.42 � 0.28 for patients with CHF versus 1.76 � 0.36 (p � 
0.02) in normals. There was no difference in ﬁber area 
between the groups. Figure 2 illustrates capillaries/mm2 for 
all subjects categorized by MET level. No differences were 
detected in ﬁber diameter between groups. 
Pearson correlation analysis was performed separately on 
patients with CHF and on normal subjects to demonstrate 
relationships between all markers of aerobic capacity and 
peak VO2. No signiﬁcant relationships were found in the 
normal group. A signiﬁcant inverse relationship was found 
between maximal oxygen consumption and capillary density 
and also between total exercise time and capillary density in 
patients with CHF (Fig. 3). 
DISCUSSION 
The results of this study show that decreases in capillary 
density may be partially responsible for exercise intolerance 
in patients with mild to moderate CHF in the absence of 
other major peripheral skeletal muscle alterations. Previous 
studies comparing predominantly class III–IV patients with 
CHF and healthy subjects with aerobic capacities �8 
METs have clearly demonstrated that skeletal muscle alter­
ations in oxidative enzymes, ﬁber type, and contractile 
proteins are partially responsible for early anaerobic metab­
olism and exercise intolerance. In this study, we found 
differences in capillary density within subgroups of patients 
with CHF (Fig. 2), and inverse relationships between 
Table 2. Relative Content of Myosin Heavy Chain (%) in 
Patients With Class II–III CHF and Normal Subjects 
MHC I MHC IIa MHC IIx 
CHF 36.9 � 14.6 34.7 � 9.6 28.3 � 13.6 
Normal Subjects 41.0 � 8.6 37.5 � 10.3 21.5 � 6.5* 
*Denotes p �0.05. 
capillary density and two aerobic markers, maximal oxygen 
consumption and total exercise time in patients with CHF 
(Fig. 3). Taking into account previous studies in normal 
subjects, these results were unexpected and counterintuitive. 
On the basis of exercise training studies, we expected a 
strong positive relationship between capillary density and 
oxidative capacity. These results suggest that a maladaptive 
process is active in the peripheral skeletal muscle in CHF. 
Capillary density and aerobic capacity. The capillary bed 
in skeletal muscle functions mainly to supply oxygen to 
muscle ﬁbers. Therefore, skeletal muscle capillary density 
has a strong positive relationship with peak VO2 in normal 
subjects. In humans, exercise training results in an increase 
in the number of capillaries/muscle ﬁber and an increase in 
the number of capillaries/mm2 of muscle (11). Interestingly, 
in other animals, increases in capillary density precede 
changes in the activity of oxidative enzymes and changes in 
contractile protein composition in models of ﬁber type 
transformation (19). Therefore, angiogenesis probably plays 
a critical role in adaptive responses to functional demand, 
where it correlates with improvements in endurance and 
oxidative capacity (10,11,20). 
The results of this study suggest that patients with CHF 
and with severely compromised aerobic capacities may have 
a compensatory, maladaptive angiogenic response to exer­
cise intolerance. In addition, we postulate that as CHF 
worsens, capillary density changes may occur before major 
enzyme or contractile protein changes. These two postulates 
are supported by the weak but consistent trend that four of 
ﬁve aerobic enzymes are decreased in patients with CHF 
Table 3. Skeletal Muscle Enzyme Activity in Patients With 
Class II–III CHF and Normal Subjects (mol/kg protein/h) 
Enzyme CHF Normal 
Hexokinase 0.4 � 0.1 0.4 � 0.1 
Lactate dehydrogenase 45.7 � 15.4 35.6 � 13.5 
Phosphofructokinase 11.7 � 3.0 9.9 � 2.3 
Phosphorylase 8.2 � 2.9 6.2 � 1.4* 
Citrate synthetase 3.7 � 0.9 3.5 � 0.9 
3-Hydroxyl-CoA dehydrogenase 2.8 � 1.2 3.8 � 0.6† 
Malic dehydrogenase 5.7 � 1.7 6.1 � 2.6 
Succinic dehydrogenase 2.4 � 0.8 3.1 � 0.8* 
Cytochrome C oxidase 75.3 � 27.0 84.1 � 21.2 
*Denotes p � 0.05. †Denotes p � 0.001. 
Figure 1. Comparison of endothelial cell/muscle ﬁber ratio (mean � SD) between patients with ambulatory class II–III CHF and normal 
subjects (*p � 0.02). 
compared with normals, and MHC IIx is greater in CHF 
without a concomitant decrease in MHC I. Worsening 
CHF may completely shift the enzyme panel toward a 
signiﬁcant decrease in all aerobic enzymes and a reduction 
in MHC I compared to normal subjects. 
Role of peripheral hemodynamics and metabolism. Al­
though it is known that patients with CHF have a reduced 
blood ﬂow to exercising skeletal muscle when compared to 
normal subjects, several studies have demonstrated that anaer­
obic metabolism in skeletal muscle during exercise in patients 
with CHF is not totally due to hypoperfusion (21–24). These 
observations have been conﬁrmed by 31P-NMR (nuclear 
magnetic resonance) studies showing early anaerobic metabo­
lism in patients with CHF when compared with normals, even 
with total occlusion of limb blood ﬂow (25,26). 
Furthermore, prior work from our laboratory demonstrated 
that patients with CHF have the ability to optimally extract 
oxygen from arteriole blood, as demonstrated by maximal 
arteriovenous-oxygen differences (A-VO2) (2). This compensa­
tory response allows patients with CHF to obtain similar 
oxygen uptakes at rest and submaximal workloads when 
compared with normals. The increases seen in the capillary bed 
cause an adjunctive increase in blood volume, thereby enhanc­
ing oxygen extraction. This study demonstrates that the num­
ber of ﬁbers being subserved by capillaries is greater in CHF 
muscle compared to normal muscle (the capillary-to-ﬁber ratio 
is lower), but lower as the CHF group’s aerobic capacity 
decreases. Therefore, there is a greater potential for maximiz­
ing oxygen removal in CHF. We postulate that a decreased 
capillary density to the working muscles may contribute to 
the earlier onset of skeletal muscle anaerobic metabolism in 
ambulatory patients with class II–III CHF. 
Interplay between cardiac output and skeletal muscle. 
This study has identiﬁed reduced capillary density as a 
possible contributor to exercise intolerance in patients with 
CHF. This study also demonstrates that capillary density 
can be altered independent of other major skeletal muscle 
alterations. These ﬁndings do not exclude an interplay 
between cardiac reserve and the periphery skeletal muscle. 
One limitation of this study was that cardiac output was not 
measured. Wilson et al. (27) have demonstrated that pa­
tients with CHF with normal cardiac output response to 
exercise had skeletal muscle abnormalities. Interestingly, 
this subgroup responded well to exercise training. Because 
no study has thoroughly examined central hemodynamic 
and peripheral alterations simultaneously or the feasibility of 
reversing skeletal muscle alterations with a long-term exer­
cise program, it is difﬁcult to ascertain the extent each is 
contributing to the observed exercise intolerance. Decreased 
cardiac reserve is a likely mechanism for early fatigue in 
patients with CHF; however, identifying the peripheral 
changes that occur, and their potential reversibility due to 
deconditioning, would not only help solve the puzzle of 
skeletal muscle pathophysiology in CHF compared to 
deconditioned normal subjects, but also aid in therapeutic 
interventions for all patients with CHF. 
Figure 2. Comparison of endothelial cell/muscle ﬁber ratio (mean � SD) between all subjects categorized by MET level (*p � 0.05 vs. 
CHF 4–5 METs and p � 0.01 vs. CHF �5 METs; **p � 0.01 vs. CHF �5 METs; ***p �0.05 vs. CHF �5 METs). 
Possible explanations for the inverse relationship be­
tween capillary density and aerobic capacity. Increased 
capillary density for patients with low MET levels may 
reﬂect the body’s attempt to maintain metabolic demands of 
the periphery that are compromised as a result of an 
abnormal cardiac output response to exercise. This may 
explain the tiered levels of endothelial cell/muscle ﬁber seen 
in CHF in Figure 2 and the inverse relationships illustrated 
in Figure 3. These inverse relationships were not found in 
the normal subjects (data not shown). 
In addition, endothelial growth may also be stimulated by 
an increased need to clear waste products, primarily lactate, 
shown to accumulate in CHF. In subgroups of patients with 
CHF, activities of daily living are performed at high 
percentages of an individual’s maximal capacity, at or near 
anaerobic threshold. It is possible that this represents an 
exercise training stimulus for the skeletal muscle. For 
example, home activities such as grocery shopping, food 
preparation while standing, dish washing, simple lawn care 
or light walking require MET levels of 2.5 to 3.5, equivalent 
to 60% to 70% of maximal oxygen consumption in a patient 
with a MET level of 4. This is well within a training range 
to initiate a training response in skeletal muscle. Most of 
patients with CHF in our study reported an independent 
life that included a number of activities requiring 2.5 to 3.5 
MET levels. In response to performing continuous bouts of 
activity per day that are 60% to 70% of maximal oxidative 
capacity, endothelial cell proliferation may occur in patients 
with CHF that parallel exercise training at or above anaer­
obic threshold in normals. 
Myosin heavy-chain isoforms and enzymes. Despite 
ﬁnding signiﬁcant differences in vascular density, we did not 
observe markedly signiﬁcant differences in two other tradi­
tional indicators of aerobic capacity, myosin heavy-chain 
(MHC) isoforms and enzymatic proﬁle. Although two of 
ﬁve aerobic enzymes, 3-hydroxyl-CoA dehydrogenase and 
succinic dehydrogenase, were found to be higher in normals 
versus CHF patients, we do not believe this would account 
for the difference in aerobic capacity. The MHC isoforms 
show no relationship to oxygen consumption, but MHC IIx 
in CHF patients is higher compared to normals. 
Our previous study showed 3-hydroxyl-CoA dehydroge­
nase and succinic dehydrogenase to be different, and ﬁber 
typing (comparable to MHC in the present study) to be 
shifted more toward a glycolytic ﬁber type. Careful exami­
nation of other studies measuring capillary density reveals 
similar ﬁndings. Drexler et al. (7) reported a reduced 
capillary length density in CHF subjects with MET levels of 
4.6, and Lipkin et al. (9) reported normal values for CHF 
patients with MET levels of 3.3. These three studies, along 
with the present study, demonstrate a potential inverse 
relationship between capillary density and aerobic capacities 
�4 METs. 
Sensitivity of CD-31. The recognition of the importance 
of vascularity to tumor growth (metastasis) has led to the 
development of cell-speciﬁc monoclonal antibodies that can 
Figure 3. Plots of the relationship between capillary density and 
aerobic markers’ maximal oxygen consumption and total exercise 
time for patients with CHF. 
be used to directly identify endothelial cells in histologic 
sections. Even among cell-speciﬁc antibodies, antigen hetero­
geneity is an important feature, and CD-31 is regarded as the 
most sensitive and speciﬁc marker for endothelial cells. Using 
immunohistochemical techniques, Wlinder et al. (28) reported 
that microvascular density in tumors was correlated with a 
decrease in survival. Horak et al. (29) likewise used immuno­
histochemical techniques and cell-speciﬁc monoclonal anti­
bodies to demonstrate that neovascularization in a tumor was 
associated with a decreased survival in patients. In their study, 
CD-31 was more sensitive than von Willebrand factor in the 
quantiﬁcation of vascular density. Tenaglia and colleagues (30) 
recently reported that the presence of neovascularization, as 
demonstrated by CD-31 (not von Willebrand factor) immu­
nostaining, in coronary atherectomy samples was associated 
with unstable coronary syndromes. Our study is the ﬁrst to 
report vascular density in human skeletal muscle utilizing 
endothelial cell-speciﬁc monoclonal antibodies. 
Conclusions. This is the ﬁrst study that has attempted to 
compare extremely sedentary normal subjects (MET �6) to 
mild to moderate class II–III CHF patients. The results of 
the present study provide a possible explanation for leg 
fatigue, one of the hallmark symptoms of exercise intoler­
ance in patients with ambulatory class II–III CHF. The 
results also suggest substrate delivery to skeletal muscle can 
be impaired at the microvascular level (i.e., capillary density) 
without other major concomitant intrinsic abnormalities in 
skeletal muscle. We postulate that within groups of CHF 
patients there may be a discordant change in capillary 
density that is inversely related to aerobic capacity. The 
stimulus for this proposed angiogenesis remains unknown. 
This study does not exclude the possibility that an attenu­
ated cardiac reserve may be primarily responsible for exercise 
intolerance in CHF and supports the need for longitudinal 
studies that simultaneously examine how cardiac output and 
skeletal muscle changes affect aerobic capacity in compen­
satory CHF patients. 
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